bausch and lome for eye care, and one for pharma and one for medical aesthetics which is top of the fieldr that they can unlock value by splitting up in a more bite size enterprises that can focus on what they do best so let's check in with joe pap yashgs the chairman and ceo and frequent guest of "mad money" of bausch health companies. welcome back to "mad money." >> hi, jim great to be with you today so, joe, you got to help me here you got this thing is selling at 27% organic growth you have i pharma business that are unsaleable and bausch is the single best name in eye care any one of these should be a premium multiple you trade six times earnings know you have the floor pt i don't get it >> well, jim, i'm going to go back to your comment in may of 2016 when i joined you talked about the challenges i faced. you clearly said i had too much debt you're absolutely correct. that was like $30 mrs. plus billion. i worked on reducing the debt. i brought the debt down by $10 billion. there is still something we need to do further. number two, we resolved the legacy legal issues of the company

bausch. but jnj should be great, too can't own them all going in next year, you want safety stocks with real earnings and catalysts, which is why i like the three big pharmaories bausch health, which we own for the charitable trust glaks o glaxosmithkline. let's take some calls. george in florida. george >> hi, jim how are you? greetings from florida >> george, i'm getting better every day. oh, man, you lucky dog what's going on? >> i'm calling about a company that's called nvax and it came out with a vaccine at 90% effective, easier to store than pfizer and has recently been approved by the eu and the w.h.o. so just to try to get your feelings on the company. thank you. >> well, i think these stocks, i like pfizer in this group. i listen to, you know what, they had, they had stan eck on the "closing bell. sounded good, but i think pfizer's the only one of the vaccines all right. we're in a new world, people we need stocks with real earnings and real catalysts, too. that's why i like bausch health. glaxosmithkline and jnj. a few weeks ago, sam freed offered a class on crypto. he's doing the same for cramerica tonight. then nobody wants to think about buyi